Literature DB >> 32606163

Treatment Outcome of Resection of Disseminated Peritoneal Metastases from Colorectal Cancer.

Gaku Ohira1, Hideaki Miyauchi2, Koichi Hayano2, Michihiro Maruyama2, Shunsuke Imanishi2, Toru Tochigi2, Tetsuro Maruyama2, Toshiharu Hanaoka2, Koichiro Okada2, Hisahiro Matsubara2.   

Abstract

AIM: To show the treatment outcomes of disseminated nodule resection for peritoneal metastasis of colorectal cancer and describe the details of cured cases. PATIENTS AND METHODS: From January 2001 to December 2016, patients who underwent disseminated nodule resection of colorectal adenocarcinoma with no macroscopic residual tumor in our institution were retrospectively analyzed for clinicopathological factors associated with prognosis.
RESULTS: Forty-one cases were included in this study. The 3-year relapse-free survival was 12.5%, and the 5-year overall survival was 38.4%. In a multivariate analysis, lack of post-operative adjuvant chemotherapy and pre-operative carbohydrate antigen 19-9 over 100 IU/l were extracted as independent factors associated with short relapse-free survival, respectively. Among 41 cases, 32 were followed-up 5 years after surgery and five (15.6%) survived without relapse and were regarded as 'cured'.
CONCLUSION: More than a few cases of colorectal peritoneal metastasis, which is thought to be difficult to cure, were cured by resection of disseminated nodules without resorting to highly invasive treatment. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Colorectal cancer; nodule resection; peritoneal metastasis

Mesh:

Year:  2020        PMID: 32606163      PMCID: PMC7439882          DOI: 10.21873/invivo.11988

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  17 in total

1.  Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: a prospective study.

Authors:  A L A Bloemendaal; V J Verwaal; S van Ruth; H Boot; F A N Zoetmulder
Journal:  Eur J Surg Oncol       Date:  2005-08-03       Impact factor: 4.424

2.  The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI).

Authors:  M Bushati; K P Rovers; A Sommariva; P H Sugarbaker; D L Morris; Y Yonemura; C A Quadros; S P Somashekhar; W Ceelen; P Dubé; Y Li; V J Verwaal; O Glehen; P Piso; J Spiliotis; M C C Teo; S González-Moreno; P H Cashin; K Lehmann; M Deraco; B Moran; I H J T de Hingh
Journal:  Eur J Surg Oncol       Date:  2018-07-20       Impact factor: 4.424

3.  Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach?

Authors:  Paul H Sugarbaker; David P Ryan
Journal:  Lancet Oncol       Date:  2012-08       Impact factor: 41.316

4.  Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy?

Authors:  Diane Goéré; David Malka; Dimitri Tzanis; Vinicius Gava; Valérie Boige; Clarisse Eveno; Léon Maggiori; Frédéric Dumont; Michel Ducreux; Dominique Elias
Journal:  Ann Surg       Date:  2013-06       Impact factor: 12.969

5.  [Neoadjuvant chemotherapy for advanced colorectal cancer].

Authors:  Gaku Ohira; Hideaki Miyauchi; Kazufumi Suzuki; Takanori Nishimori; Takayuki Tohma; Kazuo Narushima; Hisahiro Matsubara
Journal:  Gan To Kagaku Ryoho       Date:  2013-11

6.  Survival and Prognostic Factors for Metachronous Peritoneal Metastasis in Patients with Colon Cancer.

Authors:  Hiroshi Nagata; Soichiro Ishihara; Keisuke Hata; Koji Murono; Manabu Kaneko; Koji Yasuda; Kensuke Otani; Takeshi Nishikawa; Toshiaki Tanaka; Tomomichi Kiyomatsu; Kazushige Kawai; Hiroaki Nozawa; Toshiaki Watanabe
Journal:  Ann Surg Oncol       Date:  2016-12-19       Impact factor: 5.344

7.  Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis.

Authors:  Ming-Shian Tsai; Yen-Hao Su; Ming-Chih Ho; Jin-Tung Liang; Tzu-Ping Chen; Hong-Shiee Lai; Po-Huang Lee
Journal:  Ann Surg Oncol       Date:  2006-11-14       Impact factor: 5.344

8.  Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients.

Authors:  Edward A Levine; John H Stewart; Perry Shen; Gregory B Russell; Brian L Loggie; Konstantinos I Votanopoulos
Journal:  J Am Coll Surg       Date:  2013-12-21       Impact factor: 6.113

9.  Colorectal cancer survival: An analysis of patients with metastatic disease synchronous and metachronous with the primary tumor.

Authors:  Rajiv Kumar; Timothy J Price; Carol Beeke; Kunal Jain; Gargi Patel; Rob Padbury; Graeme P Young; David Roder; Amanda Townsend; Sarwan Bishnoi; Christos S Karapetis
Journal:  Clin Colorectal Cancer       Date:  2013-11-13       Impact factor: 4.481

10.  Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin.

Authors:  Joerg O W Pelz; Terence C Chua; Jesus Esquivel; Alexander Stojadinovic; Joerg Doerfer; David L Morris; Uwe Maeder; Christoph-Thomas Germer; Alexander G Kerscher
Journal:  BMC Cancer       Date:  2010-12-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.